BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia

뉴스 본문을 불러오고 있어요.

BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia | 웨이프 WAPE

BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia

기사 요약

관련 종목

댓글 —